INNOVATIVE THERAPIES BASED ON A NEXT-GENERATION DRUG DELIVERY PLATFORM

About Us

At MDimune, we are passionate about changing the world by developing innovative therapeutics.

History

FOUNDATION ~ 2019
2018
12
  • Awarded a Post-TIPS (Tech Incubator Program for Startup) grant and Global Marketing grant
05
  • Signed investment contract with STIC Investments Inc.
  • Selected as a designated company for alternative military services by Seoul Regional Military Manpower Administration
04
  • Selected for an Exclusive Consultant Support project for Innovative Biotherapeutics R&D by Korea Food and Drug Administration
03
  • Awarded the grand prize for the biotech division of the Korea Industrial Enterprise Award by Money Today for the second consecutive year
  • Signed investment contracts with The Wells Investment, Invest Korea, LNS Venture, and InterValue Partners
2017
12
  • Signed a joint development agreement with Institute for Refractory Cancer Research at Samsung Medical Center for brain cancer therapeutics
11
  • Signed a joint development agreement with Hypoxia-related Disease Research Center at Inha University Medical School for brain disease therapeutics
03
  • Received the grand prize for the biotech division of the Korea Industrial Enterprise Award by Money Today
  • Signed a business agreement with KBIO Center for New Drug Development at Osong
01
  • Signed an MOU with Hanlim Pharmaceuticals Inc. for development of age-related macular degeneration therapeutics
  • Signed an MOU with SCM Lifescience for co-development of atopy therapeutics
2016
10
  • Relocated the headquarters and research center
09
  • Awarded a TIPS (Tech Incubator Program for Startup) grant by the Small and Medium Business Administration
  • Selected for an Investors-linked R&D project by Ministry of Trade, Industry and Energy
08
  • Received investments, including Institutional Investors
05
  • Launched an MDimune R&D center under Korea Industrial Technology Association
03
  • Selected for TIPS (Tech Incubator Program for Startup) by the Small and Medium Business Administration
  • Signed investment contract with Innopolis Partners, LLC
2015
10
  • Certified as a venture company by Korea Technology Finance Corporation
05
  • Signed a technology transfer agreement, “Proprietary drug delivery technology based on artificial exosome”
04
  • Founded MDimune Inc.

Certification Status

벤처기업확인서
(기술보증기금)
/
/
상표등록
Bionanosome
(대한민국)
상표등록
바이오드론
(대한민국)
상표등록
BioDrone
(대한민국)
/